Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Inflammatory Bowel Diseases

Free Subscription Articles published in J Gastroenterol Retrieve available abstracts of 73 articles: HTML format

Single Articles

July 2026
1. XU W, Wang W, Song L
   Letter to the Editor to "Volatomics-based biomarkers for non-invasive diagnosis and monitoring of inflammatory bowel disease".
   J Gastroenterol. 2026 Jul 16. doi: 10.1007/s00535-026-02483.
   PubMed    
   
   
   June 2026
2. TAKIKAWA T, Kakuta Y, Kikuta K, Haruyama S, et al
   Clinical characteristics of acute pancreatitis in patients with inflammatory bowel disease: a nationwide survey in Japan.
   J Gastroenterol. 2026 Jun 29. doi: 10.1007/s00535-026-02476.
   PubMed     Abstract available
   
   
   
3. PENG R, Lin L, Ye C
   Comment on: Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease.
   J Gastroenterol. 2026 Jun 19. doi: 10.1007/s00535-026-02466.
   PubMed    
   
   
   
4. ZHANG X, Zhu J, Wei F, Bu L, et al
   Regulatory mechanism of the RNF168-SCCA1-MYH9 signaling axis in the response of ulcerative colitis.
   J Gastroenterol. 2026 Jun 17. doi: 10.1007/s00535-026-02458.
   PubMed     Abstract available
   
   
   May 2026
5. FAN X, Zhang G
   Comment on "Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease": treatment comparison or treatment sequencing?
   J Gastroenterol. 2026 May 27. doi: 10.1007/s00535-026-02451.
   PubMed    
   
   
   
6. CHENG W
   Comment on "Risk of extraintestinal cancer in patients with inflammatory bowel disease: a multicenter retrospective cohort study in Japan".
   J Gastroenterol. 2026 May 21. doi: 10.1007/s00535-026-02450.
   PubMed    
   
   
   
7. HORIUCHI I, Horiuchi A, Sugimoto K
   Selective IL-23 inhibitors in ulcerative colitis: current evidence and perspectives for multimodal personalized treatment: a narrative review.
   J Gastroenterol. 2026 May 2. doi: 10.1007/s00535-026-02429.
   PubMed     Abstract available
   
   
   April 2026
8. AKIYAMA S, Tsuchiya K
   Reply to "Letter to "Increasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis"".
   J Gastroenterol. 2026 Apr 25. doi: 10.1007/s00535-026-02427.
   PubMed    
   
   
   
9. MATSUOKA K, Hirai F, Watanabe K, Hokari R, et al
   Correction: Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).
   J Gastroenterol. 2026 Apr 10. doi: 10.1007/s00535-026-02399.
   PubMed    
   
   
   
10. PU T, Feng R, Wang C, Zhao Y, et al
    Correction: METTL3/YTHDF1 drives M1 macrophage polarization and aggravates ulcerative colitis progression by regulating m6A modification of SerpinB5 mRNA and FBXO32-dependent NF-kappaB pathway.
    J Gastroenterol. 2026 Apr 10. doi: 10.1007/s00535-026-02398.
    PubMed    
    
    
    
11. LI X, Pan S, Li Q, Yu B, et al
    Volatomics-based biomarkers for non-invasive diagnosis and monitoring of inflammatory bowel disease.
    J Gastroenterol. 2026 Apr 9. doi: 10.1007/s00535-026-02409.
    PubMed     Abstract available
    
    
    March 2026
12. DONG B, Hou L
    Letter to "Increasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis".
    J Gastroenterol. 2026 Mar 27. doi: 10.1007/s00535-026-02378.
    PubMed    
    
    
    
13. OKADA H, Sugimoto S, Kayashima A, Mikami Y, et al
    Distinct phenotype of primary sclerosing cholangitis-associated inflammatory bowel disease.
    J Gastroenterol. 2026 Mar 19. doi: 10.1007/s00535-026-02388.
    PubMed     Abstract available
    
    
    
14. TSURUOKA N, Takedomi H, Sakata Y, Fujioka S, et al
    Prevalence and clinical impact of latent tuberculosis infection in patients with inflammatory bowel disease in Japan: a retrospective multicenter study by the IBD-Quality team.
    J Gastroenterol. 2026 Mar 10. doi: 10.1007/s00535-026-02383.
    PubMed     Abstract available
    
    
    February 2026
15. WANG X, Tu Y, Zhang S, Che T, et al
    Severity of surgical histopathological fibrosis predicted postoperative recurrence in Crohn's disease: a multi-center retrospective cohort study.
    J Gastroenterol. 2026 Feb 26. doi: 10.1007/s00535-026-02374.
    PubMed     Abstract available
    
    
    
16. OSAKA R, Naito T, Khor SS, Kakuta Y, et al
    HLA-DQB1*03:01 and HLA-DQA1*05:05 as key genetic determinants of infliximab response and immunogenicity in Japanese patients with inflammatory bowel disease.
    J Gastroenterol. 2026 Feb 6. doi: 10.1007/s00535-026-02354.
    PubMed     Abstract available
    
    
    January 2026
17. FUJIOKA S, Umeno J, Takeda T, Kinjo K, et al
    Risk of extraintestinal cancer in patients with inflammatory bowel disease: a multicenter retrospective cohort study in Japan.
    J Gastroenterol. 2026 Jan 16. doi: 10.1007/s00535-025-02333.
    PubMed     Abstract available
    
    
    
18. PU T, Feng R, Wang C, Zhao Y, et al
    METTL3/YTHDF1 drives M1 macrophage polarization and aggravates ulcerative colitis progression by regulating m6A modification of SerpinB5 mRNA and FBXO32-dependent NF-kappaB pathway.
    J Gastroenterol. 2026 Jan 4. doi: 10.1007/s00535-025-02341.
    PubMed     Abstract available
    
    
    
19. NAMBU R, Iwama I, Takeuchi I, Hagiwara SI, et al
    Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study.
    J Gastroenterol. 2026 Jan 3. doi: 10.1007/s00535-025-02334.
    PubMed     Abstract available
    
    
    
20. FUKUI S, Kishimoto M, Matsuura M, Sakamoto A, et al
    Prevalence, characteristics, and screening of spondyloarthritis in Japanese patients with early inflammatory bowel diseases: a prospective multidisciplinary study.
    J Gastroenterol. 2026;61:46-58.
    PubMed     Abstract available
    
    
    November 2025
21. NISAR M, Awan AR, Ahmad A, Saleem H, et al
    Diagnostic accuracy of anti-integrin alphavbeta6 in ulcerative colitis: a diagnostic meta-analysis.
    J Gastroenterol. 2025 Nov 13. doi: 10.1007/s00535-025-02319.
    PubMed     Abstract available
    
    
    
22. YOSHIDA A, Takagi T, Kawashima K, Moriya K, et al
    Predictive factors for primary nonresponse to biologics in ulcerative colitis: a prospective multicenter study.
    J Gastroenterol. 2025 Nov 7. doi: 10.1007/s00535-025-02313.
    PubMed     Abstract available
    
    
    
23. MAUDUIT A, Mas E, Sola-Tapias N, Menard S, et al
    Main genetic factors associated with inflammatory bowel diseases and their consequences on intestinal permeability: involvement in gut inflammation.
    J Gastroenterol. 2025;60:1323-1338.
    PubMed     Abstract available
    
    
    September 2025
24. SONG H, Zhou Y, Liu S, Zhang Q, et al
    Long-term risk of inflammatory bowel disease in patients with irritable bowel syndrome: the cross-sectional and longitudinal relationship.
    J Gastroenterol. 2025 Sep 28. doi: 10.1007/s00535-025-02304.
    PubMed     Abstract available
    
    
    
25. MATSUOKA K, Hirai F, Watanabe K, Hokari R, et al
    Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study).
    J Gastroenterol. 2025 Sep 22. doi: 10.1007/s00535-025-02299.
    PubMed     Abstract available
    
    
    
26. TSUTSUI A, Murakami Y, Nishiwaki Y, Asakura K, et al
    Nationwide estimates of patient numbers and prevalence rates of ulcerative colitis and Crohn's disease in Japan in 2023.
    J Gastroenterol. 2025 Sep 2. doi: 10.1007/s00535-025-02295.
    PubMed     Abstract available
    
    
    July 2025
27. AKIYAMA S, Ito Y, Shiroyama M, Suzuki S, et al
    Increasing age at diagnosis raises malignancy risk and aminosalicylate intolerance influences therapeutic strategies in ulcerative colitis: a multicenter I?BRITE cohort study.
    J Gastroenterol. 2025 Jul 8. doi: 10.1007/s00535-025-02279.
    PubMed     Abstract available
    
    
    
28. ZAKERSKA-BANASZAK O, Ladziak K, Kruszka D, Maciejewski K, et al
    New potential biomarkers of ulcerative colitis and disease course - integrated metagenomic and metabolomic analysis among Polish patients.
    J Gastroenterol. 2025 Jul 4. doi: 10.1007/s00535-025-02280.
    PubMed     Abstract available
    
    
    
29. KUDO T, Arai K, Iwama I, Hagiwara SI, et al
    Expert consensus on diagnostic guidelines for pediatric inflammatory bowel disease in Japan.
    J Gastroenterol. 2025 Jul 2. doi: 10.1007/s00535-025-02271.
    PubMed     Abstract available
    
    
    
30. MORI R, Ogino T, Murakami M, Kayama H, et al
    Group 1 innate lymphoid cells and inflammatory macrophages exacerbate fibrosis in creeping fat through IFN-gamma secretion.
    J Gastroenterol. 2025;60:838-853.
    PubMed     Abstract available
    
    
    May 2025
31. SAWAHASHI M, Kakuta Y, Naito T, Okazaki S, et al
    Autoantibodies against endothelial protein C receptor and integrin alphavbeta6 predict the development of ulcerative colitis.
    J Gastroenterol. 2025 May 15. doi: 10.1007/s00535-025-02263.
    PubMed     Abstract available
    
    
    
32. JUN YK, Choi Y, Shin CM, Park YS, et al
    Impact of early aggressive treatment on long-term biochemical marker patterns in inflammatory bowel disease.
    J Gastroenterol. 2025 May 2. doi: 10.1007/s00535-025-02244.
    PubMed     Abstract available
    
    
    April 2025
33. MATSUOKA K, Motoya S, Yamamoto T, Matsuura M, et al
    Post-marketing surveillance of tofacitinib in patients with ulcerative colitis in Japan: a final report of safety and effectiveness data.
    J Gastroenterol. 2025 Apr 21. doi: 10.1007/s00535-025-02249.
    PubMed     Abstract available
    
    
    
34. UENO N, Sakatani A, Ando K, Saito S, et al
    Educational interventions to enhance support for balancing work and treatment in inflammatory bowel disease patients.
    J Gastroenterol. 2025 Apr 12. doi: 10.1007/s00535-025-02248.
    PubMed     Abstract available
    
    
    March 2025
35. OGINO Y, Sadashima K, Yoshida Y, Takedomi H, et al
    Development of a capsule endoscopy scoring system for the early diagnosis of small bowel Crohn's disease.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02235.
    PubMed     Abstract available
    
    
    
36. AKIYAMA S, Hayashi R, Takasago T, Kusunoki K, et al
    Prevalence and predictability of the Chicago Classification of Pouchitis in ulcerative colitis: a multicenter study in Japan.
    J Gastroenterol. 2025 Mar 6. doi: 10.1007/s00535-025-02231.
    PubMed     Abstract available
    
    
    
37. OKABAYASHI S, Itaya T, Yamazaki H, Yanai R, et al
    Estimating cancer risk in immune-mediated inflammatory diseases exposed to varying doses of tumour necrosis factor inhibitors.
    J Gastroenterol. 2025;60:285-293.
    PubMed     Abstract available
    
    
    February 2025
38. KIM MK, Shin SH, Lee CH, Kim S, et al
    Temporal trends in obesity and its prognostic impact in Korean patients with inflammatory bowel disease.
    J Gastroenterol. 2025 Feb 26. doi: 10.1007/s00535-025-02230.
    PubMed     Abstract available
    
    
    
39. OKITA M, Takenaka K, Hirai F, Ashizuka S, et al
    Diagnostic accuracy and cut-off values of serum leucine-rich alpha-2 glycoprotein for Crohn's disease activity in the small bowel.
    J Gastroenterol. 2025 Feb 14. doi: 10.1007/s00535-025-02223.
    PubMed     Abstract available
    
    
    January 2025
40. NAGANUMA M, Shiga H, Shimoda M, Matsuura M, et al
    First-line biologics as a treatment for ulcerative colitis: a multicenter randomized control study.
    J Gastroenterol. 2025 Jan 30. doi: 10.1007/s00535-025-02216.
    PubMed     Abstract available
    
    
    December 2024
41. OKABE M, Yamamoto S, Shiokawa M, Hisamatsu T, et al
    Publisher Correction: Anti-integrin alphavbeta6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study.
    J Gastroenterol. 2024 Dec 27. doi: 10.1007/s00535-024-02203.
    PubMed    
    
    
    
42. NAGANUMA M
    Reply to "Severe ulcerative colitis: diagnostic criteria and therapy".
    J Gastroenterol. 2024 Dec 14. doi: 10.1007/s00535-024-02200.
    PubMed    
    
    
    
43. NISHIOKA K, Ogino H, Ihara E, Chinen T, et al
    Importance of rectal over colon status in ulcerative colitis remission: the role of microinflammation and mucosal barrier dysfunction in relapse.
    J Gastroenterol. 2024 Dec 13. doi: 10.1007/s00535-024-02199.
    PubMed     Abstract available
    
    
    
44. CHIBA M
    Severe ulcerative colitis: diagnostic criteria and therapy.
    J Gastroenterol. 2024 Dec 11. doi: 10.1007/s00535-024-02198.
    PubMed    
    
    
    
45. XIONG Z, Li X, Xie M, Guo J, et al
    Small extracellular vesicles derived from adipose mesenchymal stem cells alleviate intestinal fibrosis by inhibiting the FAK/Akt signaling pathway via MFGE8.
    J Gastroenterol. 2024;59:1092-1106.
    PubMed     Abstract available
    
    
    November 2024
46. OKABE M, Yamamoto S, Shiokawa M, Hisamatsu T, et al
    Anti-integrin alphavbeta6 antibody as a biomarker for diagnosing ulcerative colitis: a nationwide multicenter validation study.
    J Gastroenterol. 2024 Nov 28. doi: 10.1007/s00535-024-02176.
    PubMed     Abstract available
    
    
    
47. YASUDA M, Shiokawa M, Kuwada T, Nishikawa Y, et al
    Anti-integrin alphavbeta6 autoantibody in primary sclerosing cholangitis: a Japanese nationwide study.
    J Gastroenterol. 2024 Nov 16. doi: 10.1007/s00535-024-02169.
    PubMed     Abstract available
    
    
    
48. KOMATSU H, Morikubo H, Kimura Y, Moue C, et al
    Determination of optimal cutoff value of ulcerative colitis intestinal ultrasound index to estimate endoscopic improvement in ulcerative colitis.
    J Gastroenterol. 2024 Nov 11. doi: 10.1007/s00535-024-02172.
    PubMed     Abstract available
    
    
    September 2024
49. CHEN G, Wu X, Zhu H, Li K, et al
    Multisample lipidomic profiles of irritable bowel syndrome and irritable bowel syndrome-like symptoms in patients with inflammatory bowel disease: new insight into the recognition of the same symptoms in different diseases.
    J Gastroenterol. 2024 Sep 10. doi: 10.1007/s00535-024-02148.
    PubMed     Abstract available
    
    
    July 2024
50. MASSIRONI S, Furfaro F, Bencardino S, Allocca M, et al
    Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment-insights from Phase II and III trials.
    J Gastroenterol. 2024 Jul 9. doi: 10.1007/s00535-024-02130.
    PubMed     Abstract available
    
    
    June 2024
51. TAKAHASHI K, Morita N, Tamano R, Gao P, et al
    Mouse IgA modulates human gut microbiota with inflammatory bowel disease patients.
    J Gastroenterol. 2024 Jun 14. doi: 10.1007/s00535-024-02121.
    PubMed     Abstract available
    
    
    May 2024
52. MATSUOKA K, Yamazaki H, Nagahori M, Kobayashi T, et al
    Correction: Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study.
    J Gastroenterol. 2024 May 30. doi: 10.1007/s00535-024-02116.
    PubMed    
    
    
    
53. NAGANUMA M
    Reply to "promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy".
    J Gastroenterol. 2024 May 13. doi: 10.1007/s00535-024-02113.
    PubMed    
    
    
    
54. CHIBA M, Kimura K
    Promising modality for severe ulcerative colitis: infliximab and plant-based diet as first-line (IPF) therapy.
    J Gastroenterol. 2024 May 4. doi: 10.1007/s00535-024-02111.
    PubMed    
    
    
    
55. IMAZU N, Torisu T, Yokote A, Umeno J, et al
    Arginase 2 attenuates ulcerative colitis by antioxidant effects of spermidine.
    J Gastroenterol. 2024 May 2. doi: 10.1007/s00535-024-02104.
    PubMed     Abstract available
    
    
    April 2024
56. MAKUUCHI M, Kakuta Y, Umeno J, Fujii T, et al
    Real-world NUDT15 genotyping and thiopurine treatment optimization in inflammatory bowel disease: a multicenter study.
    J Gastroenterol. 2024 Apr 8. doi: 10.1007/s00535-024-02099.
    PubMed     Abstract available
    
    
    March 2024
57. HIRAYAMA D, Hyodo S, Morita K, Nakase H, et al
    Change in systemic steroid use and surgery rate in patients with inflammatory bowel disease: a Japanese real-world database analysis.
    J Gastroenterol. 2024 Mar 16. doi: 10.1007/s00535-024-02086.
    PubMed     Abstract available
    
    
    January 2024
58. NAGANUMA M, Nakamura N, Kunisaki R, Matsuoka K, et al
    Medical treatment selection and outcomes for hospitalized patients with severe ulcerative colitis as defined by the Japanese criteria.
    J Gastroenterol. 2024 Jan 26. doi: 10.1007/s00535-024-02079.
    PubMed     Abstract available
    
    
    
59. KOMATSU H, Morikubo H, Kimura Y, Moue C, et al
    A combination of bowel wall thickness and submucosa index is useful for estimating endoscopic improvement in ulcerative colitis: external validation of the Kyorin Ultrasound Criterion.
    J Gastroenterol. 2024 Jan 21. doi: 10.1007/s00535-024-02077.
    PubMed     Abstract available
    
    
    November 2023
60. YOKOTE A, Imazu N, Umeno J, Kawasaki K, et al
    Reply to "Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis".
    J Gastroenterol. 2023 Nov 27. doi: 10.1007/s00535-023-02064.
    PubMed    
    
    
    
61. SUN S, Lv B
    The antiferroptotic effect of indigo on ulcerative colitis.
    J Gastroenterol. 2023 Nov 23. doi: 10.1007/s00535-023-02063.
    PubMed     Abstract available
    
    
    October 2023
62. NAGANUMA M, Kobayashi T, Kunisaki R, Matsuoka K, et al
    Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02048.
    PubMed     Abstract available
    
    
    August 2023
63. WATANABE K, Nojima M, Nakase H, Sato T, et al
    Trajectory analyses to identify persistently low responders to COVID-19 vaccination in patients with inflammatory bowel disease: a prospective multicentre controlled study, J-COMBAT.
    J Gastroenterol. 2023 Aug 10. doi: 10.1007/s00535-023-02029.
    PubMed     Abstract available
    
    
    July 2023
64. PARKES G, Ungaro RC, Danese S, Abreu MT, et al
    Correlation of mucosal healing endpoints with long-term clinical and patient-reported outcomes in ulcerative colitis.
    J Gastroenterol. 2023 Jul 25. doi: 10.1007/s00535-023-02013.
    PubMed     Abstract available
    
    
    
65. SAKURAI T, Omori T, Tanaka H, Ito T, et al
    Multicenter prospective registration study of efficacy and safety of capsule endoscopy in Crohn's disease in Japan (SPREAD-J study).
    J Gastroenterol. 2023 Jul 21. doi: 10.1007/s00535-023-02017.
    PubMed     Abstract available
    
    
    
66. YOKOTE A, Imazu N, Umeno J, Kawasaki K, et al
    Ferroptosis in the colon epithelial cells as a therapeutic target for ulcerative colitis.
    J Gastroenterol. 2023 Jul 6. doi: 10.1007/s00535-023-02016.
    PubMed     Abstract available
    
    
    June 2023
67. MATSUOKA K, Yamazaki H, Nagahori M, Kobayashi T, et al
    Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study.
    J Gastroenterol. 2023 Jun 23. doi: 10.1007/s00535-023-02005.
    PubMed     Abstract available
    
    
    
68. YOSHIDA H, Shiokawa M, Kuwada T, Muramoto Y, et al
    Anti-integrin alphavbeta6 autoantibodies in patients with primary sclerosing cholangitis.
    J Gastroenterol. 2023 Jun 13. doi: 10.1007/s00535-023-02006.
    PubMed     Abstract available
    
    
    
69. SHINZAKI S, Sato T, Fukui H
    Antidiabetic drugs for IBD: a long but promising road ahead for drug repositioning to target intestinal inflammation.
    J Gastroenterol. 2023;58:598-599.
    PubMed    
    
    
    May 2023
70. MATSUOKA K, Fujii T, Okamoto R, Yamada A, et al
    Correction: Characteristics of adult patients newly diagnosed with Crohn's disease: interim analysis of the nation-wide inception cohort registry study of patients with Crohn's disease in Japan (iCREST-CD).
    J Gastroenterol. 2023 May 5. doi: 10.1007/s00535-023-01998.
    PubMed    
    
    
    April 2023
71. WATANABE S, Ogasawara N, Kobayashi S, Kirino S, et al
    Organoids transplantation as a new modality to design epithelial signature to create a membrane-protective sulfomucin-enriched segment.
    J Gastroenterol. 2023;58:379-393.
    PubMed     Abstract available
    
    
    March 2023
72. YAMAKAWA T, Kitamoto H, Nojima M, Kazama T, et al
    Correction: The association between antigenemia, histology with immunohistochemistry, and mucosal PCR in the diagnosis of ulcerative colitis with concomitant human cytomegalovirus infection.
    J Gastroenterol. 2023 Mar 8. doi: 10.1007/s00535-023-01979.
    PubMed    
    
    
    
73. NAMBU R, Arai K, Kudo T, Murakoshi T, et al
    Clinical outcome of ulcerative colitis with severe onset in children: a multicenter prospective cohort study.
    J Gastroenterol. 2023 Mar 8. doi: 10.1007/s00535-023-01972.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum